Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Novartis lung drug wins EU nod, aiming for $500M sales By Tracy Staton Oct 1, 2012 11:38am Novartis ($NVS) won European approval for its new COPD treatment Seebri Breezhaler, with potential peak sales of about $500 million. The Swiss drugmaker expects to launch by year's end. Report